Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer

Abstract

The application relates to a combination of a parvovirus and a cytokine, preferably IFNγ, for use in treating pancreatic cancer (PDAC), in particular a terminal stage of this disease.

Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the above paragraphs is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention. 
     
         11 . A combination of a parvovirus and a cytokine for use in treating pancreatic cancer. 
     
     
         12 . The combination of compounds according to  claim 11  characterized in that the use is for treating a terminal stage of pancreatic cancer. 
     
     
         13 . The combination of compounds according to  claim 11  characterized in that the use is for treating a terminal stage of pancreatic cancer characterized by peritoneal carcinosis. 
     
     
         14 . The combination of compounds according to  claim 11  characterized in that said cytokine is an interferon. 
     
     
         15 . The combination of compounds according to  claim 14  characterized in that said interferon is IFN-γ. 
     
     
         16 . The combination of compounds according to  claim 11  characterized in that said parvovirus is a rodent parvovirus. 
     
     
         17 . The combination of compounds according to  claim 16  characterized in that said rodent parvovirus is LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV) or H1 (H1-PV). 
     
     
         18 . The combination of compounds according to  claim 11  characterized in that said parvovirus is intratumorally administered and the cytokine is intraperitoneally administered. 
     
     
         19 . The combination of compounds according to  claim 11  characterized in that the combination of compounds further comprises an immunosuppressive agent. 
     
     
         20 . The combination of compounds according to  claim 19  characterized in that the immunosuppressive agent is rapamycin or cyclophosphamide. 
     
     
         21 . A method for treating pancreatic cancer comprising administering an effective amount of a combination of a parvovirus and a cytokine 
     
     
         22 . The method according to  claim 21  wherein the pancreatic cancer is a terminal stage of pancreatic cancer. 
     
     
         23 . The method according to  claim 22  wherein the terminal stage of pancreatic cancer is characterized by peritoneal carcinosis. 
     
     
         24 . The method according to  claim 21  wherein the cytokine is an interferon. 
     
     
         25 . The method according to  claim 24  wherein the interferon is IFN-γ. 
     
     
         26 . The method according to  claim 21  wherein the parvovirus is a rodent parvovirus. 
     
     
         27 . The method according to  claim 26  wherein the rodent parvovirus is LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV) or H1 (H1-PV). 
     
     
         28 . The method according to  claim 21  wherein the parvovirus is intratumorally administered and the cytokine is intraperitoneally administered. 
     
     
         29 . The method according to  claim 21  wherein the combination of compounds further comprises an immunosuppressive agent. 
     
     
         30 . The method according to  claim 29  wherein the immunosuppressive agent is rapamycin or cyclophosphamide.